- Grants since 2016
- 145
- Awarded, last 5 years (where amounts are published)
- $500k
- Funded works, last 5 years
- 1 228
- Funded works, all time
- 2 889
Grants
2021–2024 · research · SU2C CONVERGENCE™ 3.1416 RESEARCH TEAM
Multi-omic Analysis of Immune System and Microbiota Influence on Temporal and Spatial Evolution of Tumor Microenvironments
Dan Littman · Memorial Sloan Kettering Cancer Center
2021–2024 · research · SU2C CONVERGENCE™ 3.1416 RESEARCH TEAM
Integrating Gnotobiotic, Organoid, and Metabolomic Pipelines to Probe the Cancer – Microbiome Connection
Kenya Honda · Princeton University
2021–2024 · research · SU2C CONVERGENCE™ 3.1416 RESEARCH TEAM
Molecular and Biophysical Definition of Tumor – Host Interactions and Impact on Tumorigenesis and Therapeutic Response
Ileana Cristea · New York University
2021–2024 · research · SU2C CONVERGENCE™ 3.1416 RESEARCH TEAM
Integrating Microbiome and Organoid Analyses of Patient Cohorts for Immuno- oncology Therapeutic Development
Calvin Kuo · Stanford University
2021–2023 · research · SU2C-CRUK PEDIATRIC CANCER NEW DISCOVERIES CHALLENGE RESEARCH TEAM
Targeting R-loop Stability in Ewing Sarcoma
Alexander Bishop · University of Dundee
2020 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2020)
ENHANCING FERROPTOSIS TO BLOCK EWING SARCOMA METASTATIC CAPACITY
Poul H. B. Sorenson
2020 · research · SU2C Sharp Tank Early Career Scientist Award
SU2C Sharp Tank Early Career Scientist Award 2020: Catherine Marinac
Catherine Marinac
2020–2024 · research · SU2C GASTRIC CANCER INTERCEPTION RESEARCH TEAM
Early Detection and Interception of Diffuse and Intestinal Gastric Cancer
Andrew T. Chan · University of Chicago
2020 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2020)
GENOMIC AND THERAPEUTIC IMPLICATIONS OF SELECTIVE BACTERIAL AND FUNGAL COLONIZATION OF GASTROINTESTINAL MALIGNANCIES
Luis A. Diaz
2020 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2020)
UTILIZING TUMOR ORGANOIDS TO FACILITATE THE DEVELOPMENT OF EFFECTIVE STRATEGIES TO TARGET PANCREATIC CANCER WITH ENGINEERED T CELLS
Philip D. Greenberg
2020 · research · The Ziskin Prize
The Ziskin Prize 2020: Leisha A. Emens
Leisha A. Emens
2020 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2020)
HARNESSING NK CELLS TO TREAT PEDIATRIC CANCERS
David G. Kirsch
2020 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2020)
CAN SCRNASEQ-DERIVED GENE PROGRAMS PREDICT ANTI-PD-1 RESPONSE IN HIGH TMB CRC AND NSCLC PATIENTS?
Karin Pelka
2019 · research · SU2C-Peggy Prescott Early Career Scientist Award
SU2C-Peggy Prescott Early Career Scientist Award 2019: Karin Pelka
Karin Pelka
2019–2023 · research · SU2C MEG VOSBURG T-CELL LYMPHOMA DREAM TEAM
Tailoring CAR-based Immunotherapy Strategies to T-Cell Lymphoma
Helen E. Heslop · The University of Texas MD Anderson Cancer Center
2019–2025 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM GENENTECH
Atezolizumab, Androgen Receptor (AR) targeted therapy, and SBRT in Hormone Sensitive Prostate Cancer
Sean M. Mcbride · Memorial Sloan Kettering Cancer Center
2019 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2019)
RESISTANCE TO PARP INHIBITOR PLUS ANTI- PD1 THERAPY DRIVEN BY ER STRESS AND BIOACTIVE LIPIDS IN OVARIAN CANCER
Juan R. Cubillos-Ruiz
2019 · research · SU2C Golden Arrow Early Career Scientist Award
SU2C Golden Arrow Early Career Scientist Award 2019: William Freed-Pastor
William Freed-Pastor
2019 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2019)
PRECISION COMBINATORIAL IMMUNOTHERAPEUTIC TARGETING OF THYMIC STROMAL LYMPHOPOIETIN RECEPTOR (TSLPR) SIGNALING IN PEDIATRIC AND YOUNG ADULT CRLF2-REARRANGED ALL
Sarah K. Tasian
2019–2022 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAMS— COMPUTATIONALAPPROACHES TO IDENTIFYING HIGH-RISK PANCREATIC CANCER POPULATIONS
Identifying Individuals at High Risk of Pancreatic Cancer Through Machine Learning Analysis of Clinical Records and Images
Chris Sander · University of Copenhagen
2019–2027 · research · SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM GENENTECH
Combination Sacituzumab Govitecan and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer (TNBC)
Elizabeth A. Mittendorf · University of Pennsylvania
2019–2024 · research · PEDIATRIC SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Targeting Epigenetic Dysregulation in Pediatric Cancer
Kimberly Stegmaier · Great Ormond Street Hospital
2019 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2019)
NONINVASIVE MONITORING OF TUMOR PHENOTYPE BY INTERROGATION OF PLASMA CELL FREE RNA
Maximilian Diehn
2019–2022 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAMS— COMPUTATIONALAPPROACHES TO IDENTIFYING HIGH-RISK PANCREATIC CANCER POPULATIONS
Identification of Genomic and Immune Factors in High-Risk Populations for Pancreatic Cancer
Raul Rabadan · Columbia University
2019–2027 · research · PEDIATRIC SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Clinical Translation of Novel Immune- Based Combination Therapies for Pediatric Hypermutant Cancers
Uri Tabori · Great Ormond Street Hospital
2019 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2019)
UNCOVERING MUTANT TP53 DEPENDENCIES IN SPONTANEOUSLY ARISING TRIPLE-NEGATIVE BREAST CANCER
Denada Dibra
2019–2021 · research · PEDIATRIC SU2C CATALYST® RESEARCH TEAM WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Immunomodulation to Treat Poor-Prognosis Pediatric Brain Tumors
Maryam Fouladi · Hospital for Sick Children
2019 · research · The Ziskin Prize
The Ziskin Prize 2019: Silvia C. Formenti
Silvia C. Formenti
2019 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2019)
ANTIGENICITY OF MUTANT KRAS AND IMPACT ON CANCER EVOLUTION
Robert H. Vonderheide
2018–2024 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM—NEW THERAPIES CHALLENGE
Targeting SHP2 in Pancreatic Cancer
René Bernards · The Netherlands Cancer Institute
2018 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2018)
CHARACTERIZING IMMUNE VARIABILITY IN CHILDREN FOLLOWING STANDARD-OF- CARE TREATMENT TO ENABLE PRECISION
Trevor J. Pugh
2018–2024 · research · SU2C – LUSTGARTEN FOUNDATION CONVERGENCE™ RESEARCH TEAM
Computational Deconstruction of Neoantigen- TCR Degeneracy for Cancer Immunotherapy
Benjamin Greenbaum · Icahn School of Medicine at Mount Sinai
2018–2020 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM–NEW THERAPIES CHALLENGE
Adoptive Transfer of TGF-ß-Resistant TIL to Defeat Immunosuppressive PDAC
Patrick Hwu · Baylor College of Medicine
2018–2022 · research · SU2C CONVERGENCE™ RESEARCH TEAM
Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells
Constantine S. Mitsiades · Broad Institute
2018 · research · Phillip A. Sharp Innovation in Collaboration Award (Class of 2018)
DEFINING EFFECTIVE T-CELL RESPONSE IN VIRAL AND NONVIRAL GYNECOLOGIC CANCERS
Claire F. Friedman
2018–2021 · research · SU2C CONVERGENCE™ RESEARCH TEAM
Correlating Immunological Health to Cancer Susceptibility
Mark M. Davis · Buck Institute for Research on Aging
2018–2023 · research · SU2C CONVERGENCE™ RESEARCH TEAM
Machine Learning for Cancer Immunotherapy
Ernest Fraenkel · Massachusetts Institute of Technology
2018 · research · The Ziskin Prize
The Ziskin Prize 2018: Jos Jonkers
Jos Jonkers
2018–2023 · research · SU2C–LUNGEVITY FOUNDATION–AMERICAN LUNG ASSOCIATION LUNG CANCER INTERCEPTION DREAM TEAM
Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)
Avrum E. Spira · Stanford University
2018–2020 · research · PANCREATIC CANCER COLLECTIVE RESEARCH TEAM–NEW THERAPIES CHALLENGE
Combined Targeting of MEK1/2 and Autophagy for Pancreatic Cancer Therapy
Martin Mcmahon · University of Utah